Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults
The pharmacokinetics of oral zidovudine in HIV-infected children and adults are reported. Fourty-six patients were investigated. For data analysis three groups of similar size were formed: young children 4 months −4 years, n=15 (group 1), older children up to 13 years, n=16 (group 2) and young adult...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 1995
|
| In: |
Infection
Year: 1995, Volume: 23, Issue: 6, Pages: 344-348 |
| ISSN: | 1439-0973 |
| DOI: | 10.1007/BF01713563 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/BF01713563
|
| Author Notes: | U. Wintergerst, B. Rolinski, Gundula Notheis, B.H. Belohradsky, F.-D. Goebel, Ilse Grosch-Wörner, Mechtild Vocks-Hauck, V. Wahn, K.-M. Debatin, the German Multicenter Study AIDS and Children |
| Summary: | The pharmacokinetics of oral zidovudine in HIV-infected children and adults are reported. Fourty-six patients were investigated. For data analysis three groups of similar size were formed: young children 4 months −4 years, n=15 (group 1), older children up to 13 years, n=16 (group 2) and young adults, n=15 (group 3). After a single oral dose repeated blood samples were taken 1/2 hourly during a period of 4 hours and zidovudine concentrations in plasma were determined by high performance liquid chromatography. For better comparison of dose dependent parameters peak concentrations (Cmax) and the area under the time-concentration curves (AUC) were normalized either to the dose/body weight (bw) or the dose/body surface area (bs), respectively. Time to reach peak concentrations and mean terminal elimination half-life times (t1/2β=63.4±47.6, 74.9±54.9 and 56.9±16.4 min in group 1, 2 and 3, respectively, mean ± SD) were not significantly different between the three groups. With normalization to dose/bw young children in comparison to adults had significantly lower Cmax (2.7±1.3 vs. 4.6±2.4 µmol/l, p=0.016) and AUC (226±108 vs. 373±224 µmol·min/l, p=0.038). Group 2 gave intermediate values. However, with normalization to dose/bs differences in Cmax (6.5±3.3, 7.3±4.2 and 6.8±3.6 µmol/l, in group 1, 2, and 3, respectively) and AUC (563±313, 691±351 and 555±342 µmol·min/l, in group 1, 2 and 3) were not significant between the three groups. It is likely that changes in body water content with age may account for most of these differences observed. In conclusion, a similar pharmacokinetic profile was found in children older than 3 months as compared to older children or adults. |
|---|---|
| Item Description: | Gesehen am 11.09.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1439-0973 |
| DOI: | 10.1007/BF01713563 |